ArticleMolecular therapy. Advances2026

Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa.

Christine Gretzmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.